SCHEMBL13636107

SCHEMBL13636107

Cc1ccc(Oc2ccc([N+](=O)[O-])nc2)cc1NC(=O)OC(C)(C)C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.38
GAA P10253 1/20 0.38
NPC1 O15118 1/20 0.37
HPGD P15428 3/20 0.37
HTT P42858 1/20 0.37
KMT2A Q03164 3/20 0.36
MEN1 O00255 2/20 0.36
CYP1A2 P05177 2/20 0.36
CYP2C9 P11712 2/20 0.36
CYP2C19 P33261 2/20 0.36
ALOX12 P18054 1/20 0.36
BRAF P15056 1/20 0.36
MAPT P10636 2/20 0.36
LMNA P02545 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
PRMT1 Q99873 1/20 0.35
CDK8 P49336 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2D6 P10635 1/20 0.35
SCN9A Q15858 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13636122 0.88 PDK1 (0.39) KMT2AMEN1BRAFPRMT1CDK8
SCHEMBL13636115 0.88 BRAF (0.47) ALDH1A1GAAHTTKMT2AMEN1
SCHEMBL3642907 0.87 ALDH1A1 (0.41) ALDH1A1GAANPC1HTTKMT2A
SCHEMBL3642909 0.87 ALDH1A1 (0.41) ALDH1A1GAANPC1HTTKMT2A
SCHEMBL13636098 0.83 PRMT1 (0.40) ALDH1A1GAANPC1HTTKMT2A
SCHEMBL1478008 0.83 PRMT1 (0.47) ALDH1A1NPC1HPGDKMT2AMEN1
SCHEMBL29996709 0.83 PRMT1 (0.47) ALDH1A1NPC1HPGDKMT2AMEN1
SCHEMBL29996697 0.83 CDK8 (0.46) KMT2AMEN1CDK8
SCHEMBL4732688 0.83 CDK8 (0.46) KMT2AMEN1CDK8
SCHEMBL13636108 0.82 CDK8 (0.52) CDK8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8304557-B2 Fused heterocycle derivatives and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-11-06 US disclosed
US-8304557-B2 Fused heterocycle derivatives and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-11-06 US disclosed
US-20090163488-A1 FUSED HETEROCYCLE DERIVATIVES AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-06-25 US disclosed
US-20090163488-A1 FUSED HETEROCYCLE DERIVATIVES AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-06-25 US disclosed
WO-2008150015-A1 HETEROBICYCLIC COMPOUNDS AS KINASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-12-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090163488-A1 FUSED HETEROCYCLE DERIVATIVES AND USE THEREOF NOX3, NOX5, ZYX ALDH1A1 2812/4885GAA 4732/4885NPC1 2688/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.